Close Menu

Genomic Health

The firm reported that revenues from screening products rose 35 percent year over year to nearly $220 million.

The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.

The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 63 percent year over year.

Test volume for its Cologuard test was up 63 percent year over year, while test volume for Genomic Health's Oncotype DX jumped 14 percent.

Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.

Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.

While higher recurrence scores have been associated with increased mortality in women, the pattern of the association differed among male patients.

The company reported increase US and international revenues and test volumes, driven by increased adoption and expanding public and private payor coverage.

The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.

After the merger closes, the combined company will be split into four units focused on Cologuard, Oncotype Dx, international business, and pipeline efforts.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.